Egyptian healthtech startup Reme-D has closed a $1.45 million Pre-Series A funding round to expand its manufacturing capacity and widen access to affordable molecular diagnostic tests across Africa and other underserved markets.
The round was led by Anara Impact Capital, with participation from the Global Innovation Fund, Africa Health Ventures, and other investors, according to Wamda. The fresh capital will go toward scaling production, growing Reme-D’s regional footprint, and broadening its diagnostic product line to include tests for genetic diseases and cancer.
READ ALSO:African ClimateTech Funding Reaches $1.5 Billion, Surpasses Fintech for the First Time
Founded in 2023 by nanotechnology researcher Salma Tammam, Reme-D builds molecular diagnostic kits for diseases including tuberculosis, HIV, hepatitis, and HPV, a leading cause of cervical cancer in women. The company’s core innovation lies in freeze-drying and nanotechnology techniques that keep test reagents stable at room temperature, removing the need for the cold-chain refrigeration that many traditional PCR tests require. That matters in regions where unreliable electricity and weak cold storage infrastructure have long limited access to accurate, timely diagnostics.
Reme-D says its kits can lower testing costs by as much as 40 percent compared to imported alternatives while holding clinical accuracy above 95 percent sensitivity and 98 percent specificity. The startup currently operates across Egypt, Iraq, Sudan, and Kenya, with early deployments underway in Nigeria and Libya, and processes roughly 50,000 tests each month across 92 hospitals and laboratories in Egypt alone. More than 500,000 patients have been tested using its technology so far.
With the new funding, the company plans to relocate to a 1,500-square-meter facility and upgrade its manufacturing equipment, a move expected to increase production capacity tenfold, according to entARABI. Reme-D has also grown its team from five to 50 employees since its founding and recently equipped a solar-powered mobile laboratory commissioned by the World Health Organization’s Egypt office to support the country’s Ministry of Health in monitoring vector-borne diseases in remote areas.
This latest raise builds on earlier backing for the company. Reme-D secured $500,000 from the Global Innovation Fund in April to expand its room-temperature diagnostic kits, and had previously raised close to $1 million, including support from the Oman Technology Fund, per Launch Base Africa. Adoption has been especially strong among blood banks, where Reme-D’s direct molecular testing approach has cut screening turnaround times significantly compared to older two-step methods.
Reme-D’s founder has said the company measures success by whether patients across Africa and the Global South are no longer priced out of life-saving disease diagnosis. With this new capital, the startup is positioning itself to push further into cancer and genetic disease testing while strengthening its regulatory and quality assurance capabilities as it expands across the continent.
